Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumor of the gastrointestinal tract. They are thought to be derived from the interstitial cells of Cajal, the so-called pacemaker cells that regulate gastrointestinal peristaltic function. The annual incidence of GIST is approximately 10-15 per million population with some regional variation, 1 making them the most common subtype of sarcoma. More than a decade ago, systemic chemotherapy for GIST was very disappointing with response rates typically reported of 5-7 %. Surgery was and perhaps is still the only curative modality. The report of the KIT oncogene as the major driver mutation of GIST in 1998 2 coupled with the first case report 3 of a chemotherapy refractory GIST patient (with liver and peritoneal metastasis) that demonstrated a dramatic radiographic response to imatinib demonstrated one of the first successful examples of utilizing targeted therapy for oncogene addicted solid malignancies. In this review, we will summarize and highlight the historical and recent advancements in the systemic treatment of GIST in the metastatic, adjuvant, and neoadjuvant settings.
institution prefers to initiate 400 mg/day in all fit patients and escalate to 800 mg/day upon disease progression regardless of tumor mutation status. This calls into question the routine tumor mutation testing in metastatic setting for the majority of cases. Whether one should image a patient with an exon 9 mutation more frequently in this case is uncertain.
It should also be noted that only about one-third of patients will respond to this dose escalation upon disease progression and the median time of benefit of disease control with imatinib dose escalation is relatively short, estimated at 11.6 weeks. 8 Imatinib should be continued indefinitely in nonprogressing tolerant patients with metastatic disease. The importance of continuous imatinib therapy in advanced GIST patients was demonstrated from the long-term follow-up results of the phase II B2222 study 5 and updated results of the BFR14 trial, 9,10 (a randomized, open label, phase III study assessed the impact of interrupting therapy after 1 year, 3 years, or 5 years of imatinib [400 mg/day] treatment in patients with advanced GIST). Both of these trials demonstrated that interruption of imatinib therapy results in rapid disease progression even in patients who had initially achieved complete response (CR), whereas long-term continuous imatinib treatment is associated with reduced risk for disease relapse and progression. It is notable that onethird of patients were on continuous imatinib for more than 9 years on the extended B2222 study, 4 ,5 similar to the long-term survival data reported in SWOGS0033, which showed a 26 % OS at 9 years and 22 % OS at 10 years. Moreover, both of these studies confirmed safety of long-term duration of imatinib therapy with no reported new toxicity or adverse events.
11,12
In any long-term therapy, the matter of medication adherence is of potential concern. The rate of noncompliance to imatinib has been reported variably between 30-70 % using various methodologies to measure drug adherence. [13] [14] [15] We have found that in our center that around half of advanced GIST patients will exhibited some level of noncompliance to tyrosine kinase inhibitors (TKIs). 16 Multivariate analysis suggests that one of the major reasons for nonadherence is living alone social status (p=0.01), although longer duration of therapy, female gender, and older age also trended toward negatively impacting TKIs adherence, 16 which is consistent with the results of other studies. 17 Inadequate imatinib plasma blood levels have also been associated with disease progression and poor clinical outcome in patients with GIST. A retrospective pharmacokinetic analysis of the B2222 study demonstrated patients in the lowest quartile of imatinib trough levels (<1,100 ng/ml) had a shorter time to progression than patients in all other quartiles (11.3 versus 30 months; p=0.029). 18 In addition, a recent retrospective study showed that the minimal imatinib plasma level of 20 long-term responders who had been on imatinib for more than 5 years was 789 ng/ml, suggesting that perhaps even a lower imatinib plasma level maybe effective. 19 We also confirmed that the lower cutoff in our imatinib adherence study may be a more appropriate target. 16 hand-foot syndrome, diarrhea, and hypertension were mild to moderate in intensity and easily managed by dose reduction, dose interruption, and supportive treatments. This trial has led to the approval of sunitinib as the standard second-line treatment after imatinib (either progression on or intolerance to imatinib) in metastatic GIST. The small phase II studies 21, 22 showed that the efficacy and side effects of continuous dosing of 37.5 mg/ day were similar to standard intermittent dosing of 50 mg/day 4 weeks on and 2 weeks off. 
Adjuvant Therapy
The role of adjuvant therapy in GIST is slowly becoming better defined, The significant RFS benefit of adjuvant imatinib has also been shown in multiple prospective studies in China, 29, 30 Japan, 31 Korea, 32 and Europe. 33 The question of duration of adjuvant imatinib therapy has also been subsequently evaluated in some of these prospective Asian 29, 32 and European 33 trials (see Table 2 95 % CI 0.51-1.26). The 5-year OS was quite similar (100 % versus 99 %). 34 There was a nonstatistically significant trend toward the adjuvant arm in high-risk GIST patients using modified US National Institutes of Health (NIH) criteria. 34 The final data are still awaited to draw a firm conclusion.
The cm and mitotic rate ≥5/50 HPF at any site; for nongastric size ≥5 cm). 37 Although the currently available data strongly support use of adjuvant therapy in patients with resected GIST with a high risk for recurrence, the benefit of using adjuvant therapy in the intermediate risk group remains controversial. In addition, it should be noted that there are some distinct discrepancies in defining risk categories using the three most commonly used risk-stratification systems namely: 1) NIH Consensus (Fletcher) criteria, 38 2) the modified NIH (Joensuu) 39 criteria, and 3) the NCCN-Armed Forces Institute of Pathology (NCCN-AFIP) criteria 40 (see Table 3 ). The first widely accepted criteria were the NIH Consensus Criteria, 38 which used tumor size and mitotic rate to define risk category. We now know that tumor location is also an independent prognostic factor to determine risk for recurrence, as gastric GIST is generally associated with better outcome compared with all others. The NCCN-AFIP criteria 40 included tumor site in their nomogram. It is also noted that mitotic rate >5/50 HPF was considered as a high-risk category regardless of tumor size and location in the NCCN-AFIP criteria. 40 Rutkowski et al. 41 42 In our center, high risk is defined based on the Joensuu criteria, which was also used in seminal SSGXVIII/AIO trial.
It is well known that the GIST tumor mutation analysis has both prognostic and predictive value in adjuvant setting. Tumors carrying a KIT exon 9 mutation have the highest recurrence rate compared with KIT 11 mutation, wt, and PDGFRα sensitive mutation tumors (recurrence rate in descending order). Adjuvant imatinib appears to benefit the tumors with KIT exon 11 deletion mutations. This is supported by a recent study demonstrating that imatinib therapy was associated with higher RFS in patients with a KIT exon 11 deletion of any type, but not a KIT exon 11 insertion or point mutation, KIT exon 9 mutation, PDGFRα mutation, or wt tumor, although some of these patient groups were not well represented. 43 This is consistent with many studies undertaken in the metastatic setting showing that a KIT 11 mutation and PDGFRα D842V mutation are the most imatinib-sensitive and resistant, respectively. An interesting tumor genotype has been shown in a multivariable analysis 43 not significantly associated with RFS compared with tumor size, mitotic rate, and tumor location. Therefore, it remains debatable whether to the use of tumor mutation analysis in adjuvant setting to tailor treatment. In our center we do not routinely use tumor mutation analysis in the adjuvant setting as a prediction tool. 
Neoadjuvant Therapy
A summary of clinical trials can be found in Table 4 . There is a lack of phase III clinical trial data to define the precise roles of neoadjuvant therapy in locally advanced primary GIST or recurrent/metastatic GIST. Neoadjuvant therapy is generally viewed as a reasonable option for tumor downstaging, and helps reduce short-and long-term surgical morbidities, resulting in organ preservation/function, and achieve microscopic R0 resection for marginally operable GIST tumors. The safety and efficacy of neoadjuvant imatinib has been established in several prospective and retrospective studies. [44] [45] [46] [47] [48] [49] [50] Preoperative use of imatinib is recommended in the updated European 
CT = computed tomography; d(s) = day(s); DFS = disease-free survival; DSOS = disease specific overall survival; mF/U = median follow-up; mo(s) = month(s); mPFS = median progression-free survival; OS = overall survival; PD = progressive disease; PET = positron emission tomograpghy; PR = partial response; pt = patient; RR = response rate; SD = stable disease; yr(s) = year(s).
OncOlOgy & HematOlOgy Review 52 In this study, R0 resection rate was achieved in most patients (77 %). The estimated 2-and 5-year disease-free survival (DFS) is 77%
and 53 %, respectively; the estimated 2-and 5-year OS is 97 % and 77 %, respectively. 45 The rationale for choosing 8 to 12 weeks as the duration of imatinib in this study is based on medial time to PR to imatinib in metastatic setting at time. 4 The low response rate in this study is likely compounded by the insensitivity of standard RECIST criteria in evaluating imatinib-treated GIST given that the metabolic response to imatinib as measured by fludeoxyglucose-positron emission tomography (FDG-PET)
scan in the separate analysis of the same phase II study was 85 %. 53 This metabolic response can be seen as early as 7 days especially in exon 11 mutation-positive GIST tumors. 53 The well-documented evidence of early response detection as assessed by PET scan compared with standard RECIST is noteworthy, especially in the context of early studies reporting that more than 3 months was required before a PR as defined by standard RECIST criteria was met.
A second neoadjuvant study published by McAuliffe et al. 46 also demonstrated a remarkable response rate based on PET imaging. In this phase II study, 19 patients were randomized to receive a brief course of neoadjuvant imatinib (300 mg bid for 3, 5, or 7 days) prior to surgery Although PET scanning has been proved to be highly sensitive in early assessment of GIST tumor response to imatinib especially when early prediction of response is useful in situations such as preoperative cytoreductive treatments, the utility of PET scans in preoperative setting is less clear. There are no randomized data supporting use of this image modality versus traditional CT scans. In addition, the metabolic response evaluated by PET scan seems to poorly correlate with pathologic response as seen in the above study. In addition, another study showed that the complete metabolic response seen on PET scan offers only 17 % chance for pathologic CR. 54 Choi et al. 55 recently published CT criteria to define tumor response to imatinib based on a combination of the values of tumor size and tumor density on CT, which is a 10 % decrease in tumor size or a more than 15 % decrease in tumor density at 2 months of treatment.
This modified CT response evaluation criteria had a sensitivity of 97 % and a specificity of 100 % in identifying PET responders compared with 52 % and 100 % by RECIST criteria, respectively. 55 Furthermore, this study demonstrated that this criteria seems to better correlate with clinical outcomes than standard RECIST criteria, at least in imatinib-treated GIST. 56 In our center, we prefer to use standard CT imaging to evaluate preoperative resectable primary GIST who were giving preoperative imatinib 400 mg until maximum tumor response (up to 1 year) followed by en bloc resection. The median duration of treatment was 9 months (2-12 months). R0 resection rate was 78 % similar to the rate reported by RTOG 0132/ACRIN6665. 44 According to the RECIST criteria, the PR rate was 43 % and SD rate was 57 %. After a median follow-up of 48 months, 4-year OS and DFS were 100 % and 64 %, respectively.
In a retrospective subanalysis of the BFR14 trial, 49 which prospectively studied interrupted versus continuous imatinib in 434 patients with advanced GIST, 25 patients were identified with nonmetastatic primary GIST.
Fifteen (60 %) had a PR and nine (36 %) went on to resection. Of those nine patients, median preoperative imatinib treatment duration was 7.3 (range 3.4-12) months, and seven (77 %) had an R0 resection, which is comparable with the rate reported by previous studies. Outcomes in patients who had surgery following preoperative imatinib were comparable with those with localized intermediate and high-risk GIST in the subgroup of operated patients, whereas those who did not undergo surgery behaved similarly to those with metastatic GIST. Although this result needs to be interpreted cautiously as selection bias does exist in this retrospective analysis. Patients who responded well to imatinib were more likely to be able to proceed to surgery and therefore had much better outcomes than those who did not.
In a study of radiologic assessment of response of GIST tumors to neoadjuvant imatinib prior to successful surgical resection, the plateau in the imatinib treatment response, defined as <10 % reduction in longest axial diameter on two consecutive CT scans beyond the best response, was seen at a median interval of 34 weeks (range, 26-41 weeks) and correlated with 45 % (range, 35-45 %) tumor shrinkage. 57 This is consistent with the literature and our experience. There is general consensus that there is little benefit of continuing imatinib beyond maximal response in terms of The dose of imatinib used in the preoperative setting has been either 400 mg or 600 mg daily in most prospective and retrospective studies. [44] [45] [46] [47] [48] [49] [50] There is no convincing evidence supporting tumor mutational analysis to guide the neoadjuvant use of imatinib despite its known prognostic and predictive value in adjuvant and metastatic setting. Whether a higher dose should be considered in tumors associated with relative imatinib resistance such as small bowel GIST harboring an exon 9 mutation is uncertain.
New Agents
Currently there are no approved systemic treatments after imatinib, imatinib dose escalation, sunitinib, regorafenib, and rechallenging with imatinib. There are, however, many other oral multitargeted TKIs (sorafinib, nilotinib, masitinib, dasatinib, pazopanib, motasenib, dovitinib, XL820, and ponatinib) and other molecular targeted agents such as heat shock protein 90 (HSP90) inhibitors, phosphoinositide 3-kinase (PI3K)
inhibitor, and mammalian target of rapamycin (mTOR) inhibitors that have been tried or are currently in early phase I and II trials (see Table 5 ).
Unfortunately, unlike in chronic myelogenous leukemia (CML), Nilotinib, a second-generation KIT and PDGFRα inhibitor, tested in two phase III trials 59, 60 failed to show its efficacy in both the first-and third-line, or beyond, setting.
Similarly, other TKIs such as dasatinib, 61, 62 pazopanib, 63 motesanib, 64, 65 dovitinib, 66 XL820, 67 and vatalanib 68 have been tried in early phase trials in different settings. Unfortunately results have been disappointing (see Table 5 ).
Tyrosine Kinase Inhibitors
Sorafenib is a multityrosine kinase inhibitor with activity against KIT, PDGFRα, and many other kinases. One retrospective study 69 Crenolanib is a potent imatinib-resistant PDGFR kinase inhibitor and has activity against PDGFRα D842V mutant GIST, which is found in approximately 5 % of GIST patients that have complete resistance to imatinib. 74 It is currently being tested in GIST patients with this particular mutation in a phase II trial (clinicalTrials.gov; NCT01243346).
Olaratumab is a monoclonal antibody specifically against PDGFR, including the PDGFRα D842V mutation, is also being tested in a phase II study (clinicalTrials.gov; NCT01316263).
Ponatinib is a novel kinase inhibitor structurally designed to target the T315I mutation in the ABL kinase domain. 75 It also has activity against KIT and PDGFRα secondary mutations. In the most recent pilot report of an ongoing phase II trial (clinicalTrials.gov; NCT01874665), which tested this drug in imatinib-resistant GIST patients, it demonstrated promising activity in this population with mPFS of 7 months, quite similar to sunitinib in the secondline setting, with manageable side effects. Interestingly, this study also demonstrated that ponatinib significantly inhibits KIT secondary mutation in two of the PR patients ex vivo.
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Other New Agents Linsitinib is an insulin-like growth factor receptor 1 (IGFR1) antagonist, which shows promising activity in wt GIST (15 % GIST in adults; 85 % in children) due to high expression of IGFR in wt GIST most likely as a result of loss of succinate dehydrogenase (SDH) function. In a recent report of a phase II trial, 81 linsitinib achieved 80 % SD in wt GIST patients with more than half of these patients disease controlled at 9 months, despite no objective response observed.
Palbociclib (PD-0332991) is a potent and selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that targets cell cycle machinery. It has been extensively studied in endocrine resistant breast cancer, 82 and shows some activity in liposarcoma. 83 It is planned to be tested in a phase II trial (clinicalTrials.org; NCT01907607) in GIST in the third-line setting.
Conclusions
Systemic treatments for GIST have advanced dramatically over a relatively short time period. Imatinib has been successfully used in the neoadjuvant setting to downstage tumors and reduce surgical morbidities, as well as the adjuvant setting to improve both DFS, as well as OS. With the use of imatinib, sunitinib, and regorafenib to treat advanced/metastatic GISTs in the first-, second-and third-line, respectively, mOS in stage IV GIST is 5 years and 20-30 % patients with advanced disease are still alive over 10
years. There are many newer agents in the pipeline to be tested, some of them have shown promising results especially in specific subtypes of GIST and in GIST with secondary mutations. With these newer agents, hopefully we can further improve the already significant advances in the clinical outcomes of patients with advanced GIST in the near future. n
